What is HC Wainwright’s Forecast for GALT Q2 Earnings?

Galectin Therapeutics Inc. (NASDAQ:GALT) – Equities research analysts at HC Wainwright lowered their Q2 2026 earnings estimates for shares of Galectin Therapeutics in a report released on Friday, May 15th. HC Wainwright analyst M. Keller now anticipates that the company will post earnings per share of ($0.09) for the quarter, down from their prior estimate of ($0.07). The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q3 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.37) EPS.

GALT has been the topic of a number of other reports. Wall Street Zen downgraded shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings downgraded shares of Galectin Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 4th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $11.00.

Galectin Therapeutics Trading Up 0.9%

GALT opened at $2.19 on Tuesday. The company’s 50 day moving average is $2.56 and its 200-day moving average is $3.66. Galectin Therapeutics has a 1-year low of $1.22 and a 1-year high of $7.13. The company has a market cap of $144.17 million, a P/E ratio of -5.34 and a beta of 0.45.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02).

Institutional Investors Weigh In On Galectin Therapeutics

Several hedge funds have recently added to or reduced their stakes in GALT. Bank of America Corp DE boosted its position in Galectin Therapeutics by 101.4% during the 4th quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock worth $49,000 after buying an additional 19,316 shares during the period. XTX Topco Ltd boosted its position in Galectin Therapeutics by 226.6% during the 2nd quarter. XTX Topco Ltd now owns 42,805 shares of the company’s stock worth $90,000 after buying an additional 29,699 shares during the period. Marshall Wace LLP acquired a new stake in Galectin Therapeutics during the 2nd quarter worth approximately $64,000. Vivaldi Capital Management LP boosted its position in Galectin Therapeutics by 210.0% during the 2nd quarter. Vivaldi Capital Management LP now owns 172,443 shares of the company’s stock worth $364,000 after buying an additional 116,815 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Galectin Therapeutics during the 2nd quarter worth approximately $1,580,000. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.